The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
Open accessAbstract
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS. RESULTS: Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone. CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several RCTs of 12 to 50 weeks duration and supported by meta-analyses.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
ANew Look at the Statistical Model Identification
AKAlKE, H. (2011) · Cited by 4,177
The Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P. B., Cook, J., Murray, J., Prince, M. J., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 651
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Areosa SA, 2005, Cochrane Database Syst Rev, 3, CD003154
- Smith SC, 2005, Health Technol Assess, 9, 1
- 10.1097/00005650-200305000-00004 · DOI
Cited by
Sorted by citations
Items 201–300 of 787
Samadi, A., Revenga, M. D. L. F., Pérez, C., Iriepa, I., Moraleda, I., Rodrı́guez-Franco, M. I., & Marco, J. L. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.06.021 · Cited by 37
Parsons, C., McCorry, N., Murphy, K. D., Byrne, S., O’Sullivan, D., O’Mahony, D., Passmore, P., Patterson, S. M., & Hughes, C. M. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4006 · Cited by 36
Wong, C. W. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0372-3 · Cited by 37
Glinz, D., Gloy, V., Monsch, A. U., Kressig, R. W., Patel, C., McCord, K. A., Ademi, Z., Tomonaga, Y., Schwenkglenks, M. M., Bucher, H. C., et al. (2019) · Swiss Medical Weekly · doi:10.4414/smw.2019.20093 · Cited by 36
Lecanemab slows Alzheimer's disease: hope and challenges
Mead, S., & Fox, N. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00529-4 · Cited by 36
Simulated presence therapy for dementia.
Abraha, I., Rimland, J., Lozano-Montoya, I., Dell’Aquila, G., Vélez-Díaz-Pallarés, M., Trotta, F., Cruz-Jentoft, A., & Cherubini, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011882.pub2 · Cited by 2
Moawad, M. H. E. D., Serag, I., Alkhawaldeh, I. M., Abbas, A., Sharaf, A., Alsalah, S., Sadeq, M. A., Shalaby, M. M. M., Hefnawy, M. T., Abouzid, M., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04468-y · Cited by 41
The Latest Advances in the Diagnosis and Treatment of Dementia
Hafiz, R., Alajlani, L., Ali, A., Algarni, G. A., Aljurfi, H., Alammar, O. A. M., Ashqan, M. Y., & Alkhashan, A. Y. (2023) · Cureus · doi:10.7759/cureus.50522 · Cited by 41
Ballard, C. G., Thomas, A. J., Gerry, S., Yu, L., Aarsland, D., Merritt, C., Corbett, A., Davison, C. M., Sharma, N., Khan, Z., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.11.002 · Cited by 35
Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010
Zilkens, R., Duke, J. M., Horner, B., Semmens, J. B., & Bruce, D. G. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.001 · Cited by 33
Somatic comorbidities and Alzheimer’s disease treatment
Clodomiro, A., Gareri, P., Puccio, G., Frangipane, F., Lacava, R. V., Castagna, A., Manfredi, V. G. L., Colao, R., & Bruni, A. C. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1290-3 · Cited by 35
Peters, O., Fuentes, M., Joachim, L. K., Jessen, F., Luckhaus, C., Kornhuber, J., Pantel, J., Hüll, M., Schmidtke, K., Rüther, E., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.10.001 · Cited by 33
Rodríguez-Lavado, J., Gallardo‐Garrido, C., Mallea, M., Bustos, V., Osorio, R., Hödar-Salazar, M., Chung, H., Araya‐Maturana, R., Lorca, M., Pessoa-Mahana, C. D., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112368 · Cited by 33
Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ
Ittner, A., Asih, P. R., Tan, A. R. P., Prikas, E., Bertz, J., Stefanoska, K., Lin, Y., Volkerling, A. M., Ke, Y. D., Delerue, F., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02191-1 · Cited by 35
Homma, A., Atarashi, H., Kubota, N., Nakai, K., & Takase, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151149 · Cited by 33
Vila, N., Besada, P., Viña, D., Sturlese, M., Moro, S., & Terán, C. (2016) · RSC Advances · doi:10.1039/c6ra03841g · Cited by 33
Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology?
Grizzanti, J., Corrigan, R. R., Servizi, S., & Casadesús, G. (2019) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2019/1.1212 · Cited by 31
Evaluation of clinical benefits of treatments for Alzheimer's disease
Liu, K. Y., Walsh, S., Brayne, C., Merrick, R., Richard, E., & Howard, R. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00193-9 · Cited by 31
Recent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 35
Probing enzyme-nanoparticle interactions using combinatorial gold nanoparticle libraries
Liu, Y., Winkler, D. A., Epa, V. C., Zhang, B., & Yan, B. (2014) · Nano Research · doi:10.1007/s12274-014-0618-5 · Cited by 31
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 31
Long-Term Oral Administration of Hop Flower Extracts Mitigates Alzheimer Phenotypes in Mice
Sasaoka, N., Sakamoto, M., Kanemori, S., Kan, M., Tsukano, C., Takemoto, Y., & Kakizuka, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087185 · Cited by 33
Iwanami, J., Mogi, M., Tsukuda, K., Fei, J., Ohshima, K., Wang, X., Nakaoka, H., Kan‐no, H., Chisaka, T., Bai, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.12.015 · Cited by 31
Jin, M., & Noble, J. M. (2024) · eNeuro · doi:10.1523/eneuro.0088-24.2024 · Cited by 31
Genest, D., Rochais, C., Lecoutey, C., Santos, J. S. O., Ballandonne, C., Butt‐Gueulle, S., Legay, R., Since, M., & Dallemagne, P. (2013) · MedChemComm · doi:10.1039/c3md00041a · Cited by 30
What do experts think we should do to achieve brain health?
Sahakian, B. J. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.04.002 · Cited by 31
Niznik, J. D., Zhao, X., He, M., Aspinall, S. L., Hanlon, J. T., Hanson, L. C., Nace, D. A., Thorpe, J. M., & Thorpe, C. T. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16241 · Cited by 30
Memantine Extended Release (28 mg Once Daily): A Review of Its Use in Alzheimer’s Disease
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0400-3 · Cited by 32
Han, L., Wei, S., Wang, R., Liu, Y., Zhong, Y., Fu, J., Luo, H., & Bao, M. (2025) · Biomolecules · doi:10.3390/biom15081188 · Cited by 30
Matsunaga, S., Kishi, T., & Iwata, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1710 · Cited by 29
Advances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 34
Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
Agüera-Ortíz, L., Babulal, G. M., Bruneau, M., Creese, B., D’Antonio, F., Fischer, C. E., Gatchel, J. R., Ismail, Z., Kumar, S., McGeown, W. J., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215483 · Cited by 29
Stergiou, N., Wuensche, T. E., Schreurs, M., Mes, I., Verlaan, M., Kooijman, E. J. M., Windhorst, A. D., Helboe, L., Vergo, S. B., Christensen, S., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06109-3 · Cited by 27
Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215431 · Cited by 28
Hu, W., Wang, Z., Zhang, H., Mahaman, Y. A. R., Huang, F., Meng, D., Zhou, Y., Wang, S., Jiang, N., Xiong, J., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01204-z · Cited by 28
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Reiss, A. B., Muhieddine, D., Jacob, B., Mesbah, M., Pinkhasov, A., Gomolin, I. H., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2023) · Medicina · doi:10.3390/medicina59061084 · Cited by 31
Time from Symptom Debut to Dementia Assessment by the Specialist Healthcare Service in Norway
Helvik, A., Engedal, K., Benth, J. Š., & Selbæk, G. (2018) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000487233 · Cited by 28
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 32
Persistence of Cholinesterase Inhibitor Treatment in Dementia: Insights from a Naturalistic Study
Olazarán, J., Navarro, E. T., & Rojo, J. M. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345279 · Cited by 28
Neurodegenerative Diseases: New Hopes and Perspectives
Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 29
Cunningham, E. L., Todd, S. A., Passmore, P., Bullock, R., & McGuinness, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub4 · Cited by 45
Neurotoxicity from Old and New Radiation Treatments for Brain Tumors
Soffietti, R., Pellerino, A., Bruno, F., Mauro, A., & Rudà, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310669 · Cited by 25
New molecular approaches to Alzheimer's disease
Resta, C. D., & Ferrari, M. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.010 · Cited by 26
Differential response to donepezil in MRI subtypes of mild cognitive impairment
Diaz‐Galvan, P., Lorenzon, G., Mohanty, R., Mårtensson, G., Cavedo, E., Lista, S., Vergallo, A., Kantarci, K., Hampel, H. J., Dubois, B., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01253-2 · Cited by 25
Rapp, S. R., Dressler, E. V. M., Brown, W. M., Wade, J. L., Le-Lindqwister, N. A., King, D. M., Rowland, K. M., Weaver, K. E., Klepin, H. D., Shaw, E. G., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01100 · Cited by 25
Tifratène, K., Duff, F. L., Pradier, C., Quetel, J., Lafay, P., Schück, S., Benzenine, É., Quantin, C., & Robert, P. H. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3303 · Cited by 25
The South African Society of Psychiatrists (SASOP) Treatment Guidlelines for Psychiatric Disorders
Emsley, R. A., Flisher, A. J., Grobler, G. P., Seedat, S., & Szabo, C. P. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.942 · Cited by 25
Häger, K., Baseman, A. S., Nye, J. S., Brashear, H. R., Han, J., Sano, M., Davis, B. M., & Richards, H. M. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0214-x · Cited by 24
Livingston, G., Baio, G., Sommerlad, A., de Lusignan, S., Poulimenos, S., Stephen Morris, A., Rait, G., & Hoe, J. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002252 · Cited by 24
Appetite, Metabolism and Hormonal Regulation in Normal Ageing and Dementia
Nifli, A. (2018) · Diseases · doi:10.3390/diseases6030066 · Cited by 23
Neuroprotective Effects of Amylin Analogues on Alzheimer’s Disease Pathogenesis and Cognition
Grizzanti, J., Corrigan, R. R., & Casadesús, G. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180433 · Cited by 24
Does Diet Have a Role in the Treatment of Alzheimer's Disease?
Thelen, M., & Brown‐Borg, H. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.617071 · Cited by 24
Gallagher, D., & Herrmann, N. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.46 · Cited by 25
Ren, Z., Yang, H., Zhu, C., Deng, J., & Fan, D. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c02550 · Cited by 23
Kim, Y., Kang, D. W., Kim, G. H., Kim, K. W., Kim, H. J., Na, S., Park, K. H., Park, Y. H., Byeon, G., Suh, J., et al. (2025) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2025.24.1.1 · Cited by 23
Youn, H., & Jeong, H. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.12.758 · Cited by 23
Cao, Y., Wang, N., Zhang, Q., Shen, N., Bai, J., Luo, X., & Liu, Y. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112197 · Cited by 26
Efficacy of memantine hydrochloride once-daily in Alzheimer’s disease
Kurz, A., & Grimmer, T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.945907 · Cited by 22
Gene Expression Profile and Functional Analysis of Alzheimer’s Disease
Chen, F., Guan, Q., Nie, Z.-Y., & Jin, L.-J. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513500838 · Cited by 22
Godyń, J., Zaręba, P., Łażewska, D., Stary, D., Reiner‐Link, D., Frank, A., Latacz, G., Mogilski, S., Kaleta, M., Doroż-Płonka, A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105129 · Cited by 21
Wang, H., Zong, Y., Han, Y., Zhao, J. P., Liu, H., & Liu, Y. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2027905 · Cited by 21
Formulation strategies for nose-to-brain drug delivery in Alzheimer's disease
Vohra, M., Amir, M., Sharma, A., & Wadhwa, S. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100075 · Cited by 21
Bosco, F., Ruga, S., Citraro, R., Leo, A., Guarnieri, L., Maiuolo, J., Oppedisano, F., Macrì, R., Scarano, F., Nucera, S., et al. (2023) · Nutrients · doi:10.3390/nu15153428 · Cited by 23
Maxwell, C. J., Vu, M., Hogan, D. B., Patten, S. B., Jantzi, M., Kergoat, M., Jetté, N., Bronskill, S. E., Heckman, G. A., & Hirdes, J. P. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0083-y · Cited by 21
An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer’s disease
Marcelli, S., Ficulle, E., Piccolo, L., Corbo, M., & Feligioni, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.023 · Cited by 21
Differential Pharmacological Effects on Brain Reactivity and Plasticity in Alzheimer’s Disease
Brem, A., Atkinson, N. J., Seligson, E. E., & Pascual‐Leone, Á. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00124 · Cited by 22
The pharmacological management of Alzheimer's disease
Bishara, D., Sauer, J., & Taylor, D. M. (2015) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.387 · Cited by 21
Shiue, Y., Tseng, P., Zeng, B., Chen, Y., Yang, C., Su, K., Chen, T., Wu, Y., Tu, Y., Lin, P., et al. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220420122322 · Cited by 21
Wang, G., Liu, L., Li, Y., Aschenbrenner, A. J., Bateman, R. J., Delmar, P., Schneider, L. S. S., Kennedy, R., Cutter, G., & Xiong, C. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12286 · Cited by 20
Jeong, J. H., Choi, B. Y., Kho, A. R., Lee, S. H., Hong, D. K., Lee, S. H., Lee, S. Y., Song, H. K., Choi, H., & Suh, S. W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112311 · Cited by 20
Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder
Mathys, M. L. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.11.284 · Cited by 23
Vishwas, S., Awasthi, A., Corrie, L., Singh, S. K., & Gulati, M. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109879 · Cited by 20
Clinical guidelines «Cognitive disorders in the elderly and senile persons»
Tkacheva, O. N., Yahno, N. N., Незнанов, Н. Г., Шпорт, С. В., Shamalov, N. A., Levin, O. S., Kostyuk, G. P., Gusev, E. I., Martynov, M. Y., Si, G., et al. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2025125337 · Cited by 22
Richardson, K., Savva, G. M., Boyd, P. J., Aldus, C. F., Maidment, I., Pakpahan, E., Loke, Y. K., Arthur, A. J., Steel, N., Ballard, C. G., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25010 · Cited by 21
Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact
Olazarán, J., Pardo, C. C., Fortea, J., Sánchez‐Juan, P., García‐Ribas, G., Viñuela, F., Martínez‐Lage, P., & Boada, M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01271-0 · Cited by 21
Diagnosis and Management of the Patient with Suspected Dementia in Primary Care
Holzer, S., Warner, J. P., & Iliffe, S. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0098-4 · Cited by 19
Withdrawal of Antidementia Drugs in Older People: Who, When and How?
Parsons, C. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0384-z · Cited by 20
Response of zebrafish larvae to mild electrical stimuli: A 96-well setup for behavioural screening
Steenbergen, P. J. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.03.002 · Cited by 20
San-Juan-Rodriguez, A., Zhang, Y., He, M., & Hernandez, I. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.0213 · Cited by 19
Yunusa, I. U., Alsahali, S. M., Rane, A., & Eguale, T. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210307 · Cited by 20
Tundis, R., Loizzo, M. R., Nabavi, S. M., Orhan, İ. E., Skalicka‐Woźniak, K., D’Onofrio, G., & Aiello, F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809593-5.00003-3 · Cited by 19
Effect of Cognitive Stimulation Therapy on Quality of Life: A Critical Review
Chao, I. C. I., Nicpon, K., & Roberts, M. R. (2020) · Physical & Occupational Therapy In Geriatrics · doi:10.1080/02703181.2020.1716915 · Cited by 15
Alzheimer’s Disease: Innovative Therapeutic Approaches Based on Peptides and Nanoparticles
Mota, I. F. L., de Lima, L. S., Santana, B. D. M., Gobbo, G. D. A. M., Bicca, J. V. M. L., Azevedo, J. R. M., Veras, L. G., Taveira, R. D. A. A., Pinheiro, G. B., & Mortari, M. R. (2021) · The Neuroscientist · doi:10.1177/10738584211016409 · Cited by 17
Correas, Á. G., González, G. O., Roca, M., Blanco-Gandía, M. C., Nascimento, C. M. C., Lahoz, A., Rodríguez‐Arias, M., Miñarro, J., Gómez‐Cabrera, M. C., & Viña, J. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103242 · Cited by 18
Sheikh, M., & Ammar, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1398952 · Cited by 23
Nanoparticles Based Intranasal Delivery of Drug to Treat Alzheimer’s Disease: A Recent Update
Pandey, M., Choudhury, H., Verma, R. K., Chawla, V., Bhattamisra, S. K., Gorain, B., Raja, M. A. G., & Amjad, M. W. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319999200819095620 · Cited by 18
An update on Alzheimer's disease: Immunotherapeutic agents, stem cell therapy and gene editing
Patwardhan, A. G., & Belemkar, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119790 · Cited by 19
Świetlik, D., Kusiak, A., & Ossowska, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084727 · Cited by 17
Crosstalk between Adult Hippocampal Neurogenesis and Its Role in Alzheimer’s Disease
Tiwari, V., Mishra, A., Singh, S., & Shukla, S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00119 · Cited by 19
Qi, X., Nizamutdinov, D., Yi, S. S., Wu, E., & Huang, J. H. (2024) · Biomedicines · doi:10.3390/biomedicines12112636 · Cited by 18
Lazzeroni, L. C., Halbauer, J. D., Ashford, J. W., Noda, A. M., Hernandez, B., Azor, V., Hozack, N. E., Hasson, N. K., Henderson, V. W., Yesavage, J. A., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130662 · Cited by 17
The impact of Medicare prescription drug coverage on the use of antidementia drugs
Fowler, N. R., Chen, Y., Thurton, C. A., Men, A., Rodríguez, E., & Donohue, J. M. (2013) · BMC Geriatrics · doi:10.1186/1471-2318-13-37 · Cited by 17
Alzheimer dementia: Starting, stopping drug therapy
Kim, L. D., & Factora, R. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.16080 · Cited by 19
Huisa, B. N., Thomas, R. G., Jin, S., Oltersdorf, T., Taylor, C., & Feldman, H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180684 · Cited by 17
Tezel, G., Timur, S. S., Bozkurt, İ., Türkoğlu, Ö. F., Eroğlu, İ., Nemutlu, E., Öner, L., & Eroğlu, H. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00511 · Cited by 17
New treatment modalities in Alzheimer's disease
Köseoğlu, E. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i14.1764 · Cited by 17
Pharmakologische Therapie der Alzheimer-Demenz
Müller, P., Fendt, M., & Müller, N. (2019) · Der Internist · doi:10.1007/s00108-019-0625-4 · Cited by 17
Is Aducanumab for LMICs? Promises and Challenges
Gunawardena, I. P. C., Retinasamy, T., & Shaikh, M. F. (2021) · Brain Sciences · doi:10.3390/brainsci11111547 · Cited by 19
Clinical Significance in Dementia Research
Shabbir, S. H., & Sanders, A. E. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514522539 · Cited by 17
Bhujbal, S. P., & Hah, J. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01566-w · Cited by 17
Metadata
- Authors
- Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O'Brien, J., Passmore, P., Sheehan, B., Juszczak, E., Katona, C., Hills, R., Knapp, M., Ballard, C., Brown, R., Banerjee, S., Onions, C., Griffin, M., Adams, J., Gray, R., Johnson, T., Bentham, P., & Phillips, P.
- Affiliations
- King's College London (GB)
- Churchill Hospital (GB)
- University of Leicester (GB)
- Whiston Hospital (GB)
- Newcastle University (GB)
- University of Manchester (GB)
- Fulbourn Hospital (GB)
- University of Oxford (GB)
- Inverclyde Royal Hospital (GB)
- Crichton Royal Hospital (GB)
- Queen's University Belfast (GB)
- University of Warwick (GB)
- University College London (GB)
- University of Wales (GB)
- Avon and Wiltshire Mental Health Partnership NHS Trust (GB)
- University of Cambridge (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- ORCID
- Howard, Robert
- McShane, Rupert
- Ritchie, Craig
- Baldwin, Ashley
- Barber, Robert
- Burns, Alistair
- Dening, Tom
- Findlay, David
- Holmes, Clive
- Jones, Roy
- McKeith, Ian
- Macharouthu, Ajay
- O'Brien, John
- Passmore, Peter
- Sheehan, Bart
- Juszczak, Edmund
- Katona, Cornelius
- Hills, Robert
- Knapp, Martin
- Ballard, Clive
- Brown, Richard
- Banerjee, Sube
- Gray, Richard
- Johnson, Tony
- Bentham, Peter
- Phillips, Patrick
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 893-903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151585937
- Cited by
- 782
- References
- 31
- Citations by year
- 2026: 43 · 2025: 49 · 2024: 44 · 2023: 58 · 2022: 51 · 2021: 48 · 2020: 45 · 2019: 58 · 2018: 47 · 2017: 55 · 2016: 54 · 2015: 54 · 2014: 59 · 2013: 74 · 2012: 40
- FWCI
- 52.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Leicester Research Archive (University of Leicester) (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Alzheimer's Society
- King's College London
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, donepezil, memantine, cholinesterase inhibitors, NMDA receptor antagonists, combination therapy, cognitive function, activities of daily living, functional disability, treatment continuation, community-dwelling patients, minimal clinically important difference, treatment discontinuation
- MeSH terms
- Donepezil, Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Double-Blind Method, Drug Synergism, Drug Therapy, Combination, Female, Humans, Indans, Male, Memantine, Patient Dropouts, Piperidines, Psychological Tests, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
